Biotechnology company.
AI-generated insights about Altimmune from various financial sources
The speaker has a very negative initial impression of the company's recent 'positive top line results,' calling them 'Dog poo-poo,' but admits he has not yet looked at the data in detail.
The speaker has a very negative initial impression of the company's recent 'positive top line results,' calling them 'Dog poo-poo,' but admits he has not yet looked at the data in detail.